Free Light Chain Monomer-Dimer Pattern Analysis as Non-Invasive Tool in Predicting MGUS and SMM Progression

Area of Science:

• Hematology
• Oncology
• Biochemistry

Background:

• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are precursor plasma cell disorders.
• Current risk stratification models for these conditions have limited precision and often require invasive bone marrow assessments.

Purpose of the Study:

• To evaluate the efficacy of free light chain (FLC)-monomer (M)-dimer (D) pattern analysis (FLC-MDPA) as a non-invasive tool for predicting progression in MGUS and SMM.
• To compare the predictive performance of FLC-MDPA with existing risk stratification models.

Main Methods:

• A non-invasive Western blot-based serum assay, FLC-MDPA, was applied to patients with MGUS (n=68) and SMM (n=40).
• A training set (n=50) was used to define progression criteria, and a validation set (n=46) confirmed the findings.
• Statistical analyses included sensitivity, specificity, negative predictive value (NPV), and hazard ratios (HR).

Main Results:

• FLC-MDPA demonstrated high accuracy in predicting biochemical progression (sensitivity 0.79, specificity 0.92, NPV 0.86) and clinical progression (sensitivity 0.84, specificity 0.79).
• Patients with abnormal FLC-MDPA patterns showed significantly higher progression rates (p < 0.0001).
• FLC-MDPA improved sensitivity and NPV when incorporated into a modified risk model and was independently associated with progression in multivariable analysis.

Conclusions:

• FLC-MDPA is a promising non-invasive tool for risk stratification in MGUS and SMM.
• This assay enhances predictive accuracy and negative predictive value compared to existing models.
• FLC-MDPA may reduce the reliance on invasive bone marrow assessments for managing these plasma cell disorders.